



Referenties bij MAGMA 4-2011

MDL-zorg in Suriname: het moet, het kan, het zal..., p. 100–101

1. Centraal Bureau van de Statistiek (www.cbs.nl)
2. Oudhof et al, Omvang en spreiding van Surinaamse bevolkingsgroepen in Nederland. CBS.
3. Ministerie van Gezondheidszorg Suriname, Meerjaren sectorplan gezondheidszorg
4. World Health Organization (www.who.org)
5. Google Public Data Explorer

Antivirale therapie hepatitis C, p. 113–114

1. De Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. *Vox Sang* 2009;97:1-12.
2. De Bruijne J, Bergmann JF, Weegink CJ, et al. Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. *Antivir Ther* 2010;15:765-773.
3. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology* 2006;131:997-1002.
4. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. *Gastroenterology* 2010;138:913-921.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011;364:2405-2416.
6. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011;364:1195-1206.
7. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011;365:1014-1024.
8. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011;364:1207-1217.
9. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010;362:1292-1303.
10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011;364:2417-2428.
11. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* 2010;465:96-100.

Casuïstiek – Endoscopische behandeling iatrogeen letsel: katheterisatie colon, p. 125–127

1. Eugene M. Bricker, Bladder substitution after pelvic evisceration. *Journal of Urology*, 2002; 167 (2): 1140-5 (Reprinted with permission from *Surg Clin North Am* 1950, 30: 1511–1521, 1950).
2. Sadmeet Singh & Simon Choong, Rupture and perforation of urinary reservoirs made from bowel. *World Journal of Urology*, 2004; 22: 222-6.
3. Jeffrey I Katz et al. Perforation of ileal conduit with pediatric gastroscope during endoscopy. *Urology*, 1980; 15(3): 291-3.
4. Jonathan E. Bernie & Joseph D. Schmidt, Ileal conduit perforation-iatrogenic injury and conservative management. *Urology*, 2001; 58(5):799.